Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma

Biochemical Pharmacology

Volumn 83, Issue 9, 2012, Pages 1146-1158

  Zhou, Qian ^a,b   Lui, Vivian Wai Yan ^c   Lau, Cecilia Pik Yuk ^b   Cheng, Suk Hang ^b   Ng, Margaret Heung Ling ^b   Cai, Yijun ^b   Chan, Stephen Lam ^a   Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti apoptotic survival proteins; Hepatocellular carcinoma; Microtubule; mTOR; Sustained antitumor activity

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; PROTEIN MCL 1; SURVIVIN; TEMSIROLIMUS; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; LIVER CELL CARCINOMA; MALE; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICROTUBULES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858077469     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.01.013     Document Type: Article

References (41)

1. J. He, D.F. Gu, X.G. Wu, K. Reynolds, X.F. Duan, and C.H. Yao Major causes of death among men and women in China New England Journal of Medicine 353 2005 1124 1134
2. D.M. Parkin Global cancer statistics in the year 2000 Lancet Oncology 2 2001 533 543
3. A.L. Cheng, Y.K. Kang, Z.D. Chen, C.J. Tsao, S.K. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncology 10 2009 25 34
4. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma New England Journal of Medicine 359 2008 378 390
5. F. Sahin, R. Kannangai, O. Adegbola, J.Z. Wang, G. Su, and M. Torbenson mTOR and P70S6 kinase expression in primary liver neoplasms Clinical Cancer Research 10 2004 8421 8425
6. L.D. Zhou, Y. Huang, J.D. Li, and Z.M. Wang The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma Medical Oncology 27 2010 255 261
7. T.L. Phung, K. Ziv, D. Dabydeen, G. Eyiah-Mensch, M. Riveros, and C. Perruzzi Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin Cancer Cell 10 2006 159 170
8. D. Ito, K. Fujimoto, T. Mori, K. Kami, M. Koizumi, and E. Toyoda In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer International Journal of Cancer 118 2006 2337 2343
9. S.A. Lang, A. Gaumann, G.E. Koehl, U. Seidel, F. Bataille, and D. Klein Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model International Journal of Cancer 120 2007 1803 1810
10. M.B. Atkins, M. Hidalgo, W.M. Stadler, T.F. Logan, J.P. Dutcher, and G.R. Hudes Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma Journal of Clinical Oncology 22 2004 909 918
11. T.E. Witzig, S.M. Geyer, I. Ghobrial, D.J. Inwards, R. Fonseca, and P. Kurtin Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma Journal of Clinical Oncology 23 2005 5347 5356
12. S. Faivre, G. Kroemer, and E. Raymond Current development of mTOR inhibitors as anticancer agents Nature Reviews Drug Discovery 5 2006 671 688
13. A.X. Zhu, T.A. Abrams, R.A. Miksad, L.S. Blaszkowsky, J.A. Meyerhardt, and H. Zheng Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer 117 2011 5094 5102
14. S. Mabuchi, D.A. Altomare, D.C. Connolly, A. Klein-Szanto, S. Litwin, and M.K. Hoelzle RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer Cancer Research 67 2007 2408 2413
15. C.J. Wu, M. Wangpaichitr, L. Feun, M.T. Kuo, C. Robles, and T. Lampidis Overcoming cisplatin resistance by mTOR inhibitor in lung cancer Molecular Cancer 4 2005
16. M.A. Patil, M.S. Chua, K.H. Pan, R. Lin, C.J. Lih, and S.T. Cheung An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma Oncogene 24 2005 3737 3747
17. C.Y. Tung, C.H. Jen, M.T. Hsu, H.W. Wang, and C.H. Lin A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets BMC Genomics 10 2009
18. Q. Zhou, A.K. Ching, W.K. Leung, C.Y. Szeto, S.M. Ho, and P.K. Chan Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma International Journal of Oncology 38 2011 721 731
19. D.J. VanderWeele, R.X. Zhou, and C.M. Rudin Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin Molecular Cancer Therapeutics 3 2004 1605 1613
20. L.S. Faried, A. Faried, T. Kanuma, T. Nakazato, T. Tamura, and H. Kuwano Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel European Journal of Cancer 42 2006 934 947
21. V.W.Y. Lui, A.L. Boehm, P. Koppikar, R.J. Leeman, D. Johnson, and M. Ogagan Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1 Molecular Pharmacology 71 2007 1435 1443
22. B. Hong, V.W.Y. Lui, E.P. Hui, Y.L. Lu, H.S.Y. Leung, and E.Y.L. Wong Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1 Biochemical Pharmacology 79 2010 842 852
23. V.W.Y. Lui, D.M.S. Yau, E.Y.L. Wong, Y.K. Ng, C.P.K. Lau, and Y. Ho Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells Carcinogenesis 30 2009 2085 2094
24. V.W.Y. Lui, D.M.S. Yau, C.S.F. Cheung, S.C.C. Wong, A.K.C. Chan, and Q. Zhou FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation Oncogene 30 2011 1518 1530
25. K.S. McCarty, L.S. Miller, E.B. Cox, J. Konrath, and K.S. McCarty Estrogen-receptor analyses - correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies Archives of Pathology & Laboratory Medicine 109 1985 716 721
26. L.M. Hu, J. Hofmann, Y.L. Lu, G.B. Mills, and R.B. Jaffe Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Research 62 2002 1087 1092
27. B. Singh, P.G. Reddy, A. Goberdhan, C. Walsh, S. Dao, and I. Ngai p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas Genes & Development 16 2002 984 993
28. V. Stambolic, D. MacPherson, D. Sas, Y. Lin, B. Snow, and Y. Jang Regulation of PTEN transcription by p53 Molecular Cell 8 2001 317 325
29. L. Wang, W.Y. Shi, Z.Y. Wu, M. Varna, A.H. Wang, and L. Zhou Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma Journal of Hematology & Oncology 3 2010
30. K.H. Tam, Z.F. Yang, C.K. Lau, C.T. Lam, R.W.C. Pang, and R.T.P. Poon Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma Cancer Letters 273 2009 201 209
31. G.Y. Chau, A.F.Y. Lee, S.H. Tsay, Y.R. Ke, H.L. Kao, and F.H. Wong Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma Histopathology 51 2007 204 218
32. B. Fleischer, H. Schulze-Bergkamen, M. Schuchmann, A. Weber, S. Biesterfeld, and M. Muller Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma International Journal of Oncology 28 2006 25 32
33. W. Sieghart, D. Losert, S. Strommer, D. Cejka, K. Schmid, and S. Rasoul-Rockenschaub Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy Journal of Hepatology 44 2006 151 157
34. L. Yildiz, S. Baris, O. Aydin, M. Kefeli, and B. Kandemir Bcl-2 positivity in B and C hepatitis and hepatocellular carcinomas Hepato-Gastroenterology 55 2008 2207 2210
35. Y. Yang, J. Zhu, H. Gou, D. Cao, M. Jiang, and M. Hou Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC) Medical Oncology 28 2011 796 803
36. J. Pizem, V.F. Marolt, B. Luzar, and A. Cor Proliferative and apoptotic activity in hepatocellular carcinoma and surrounding non-neoplastic liver tissue Pflugers Archiv-European Journal of Physiology 442 2001 R174 R176
37. D. Marimpietri, C. Brignole, B. Nico, F. Pastorino, A. Pezzolo, and F. Piccardi Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis Clinical Cancer Research 13 2007 3977 3988
38. N. Campostrini, D. Marimpietri, A. Totolo, C. Mancone, G.M. Fimia, and M. Ponzoni Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line Proteomics 6 2006 4420 4431
39. A. Vacca, M. Iurlaro, D. Ribatti, M. Minischetti, B. Nico, and R. Ria Antiangiogenesis is produced by nontoxic doses of vinblastine Blood 94 1999 4143 4155
40. A.K. Nowak, P.K.H. Chow, and M. Findlay Systemic therapy for advanced hepatocellular carcinoma: a review European Journal of Cancer 40 2004 1474 1484
41. A.T. Nies, J. Konig, M. Pfannschmidt, E. Klar, W.J. Hofmann, and D. Keppler Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma International Journal of Cancer 94 2001 492 499